Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy

References

• BuxbaumJNTransthyretin and the Transthyretin AmyloidosesUverskyVNFinkAProtein Misfolding, Aggregation, and Conformational DiseasesSanta Cruz, CASpringer2007259283
   Google Scholar
• ReixachNDeechongkitSJiangXKellyJWBuxbaumJNTissue damage in the amyloidoses: Transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue cultureProc Natl Acad Sci U S A200410192817282214981241
   PubMed Web of Science ®Google Scholar
• WhiteJTKellyJWSupport for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitroProc Natl Acad Sci U S A20019823130191302411687657
   PubMed Web of Science ®Google Scholar
• SchreiberGSouthwellBRRichardsonSJHormone delivery systems to the brain – transthyretinExp Clin Endocrinol19951037580
   Google Scholar
• SchreiberGThe evolution of transthyretin synthesis in the choroid plexusClin Chem Lab Med200240121200121012553420
   PubMed Web of Science ®Google Scholar
• RedzicZBSegalMBThe structure of the choroid plexus and the physiology of the choroid plexus epitheliumAdv Drug Deliv Rev200456121695171615381330
   PubMed Web of Science ®Google Scholar
• CostaRHGraysonDRDarnellJEMultiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and α1-antitrypsin genesMol Cell Biol19899141514252786140
   PubMed Web of Science ®Google Scholar
• SamadaniUCostaRHThe transcriptional activator hepatocyte nuclear factor 6 regulates liver gene expressionMol Cell Biol19961611627362848887657
   PubMed Web of Science ®Google Scholar
• CostaRHGraysonDRSite-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer regionNucleic Acids Res19911915413941451870969
   PubMed Web of Science ®Google Scholar
• QianXSamadaniUPorcellaACostaRHDecreased expression of hepatocyte nuclear factor 3 alpha during the acute-phase response influences transthyretin gene transcriptionMol Cell Biol1995153136413767862129
   PubMed Web of Science ®Google Scholar
• DicksonPWAldredARMarleyPDBannisterDSchreiberGRat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liverJ Biol Chem19862618347534783949774
   PubMed Web of Science ®Google Scholar
• LiXBuxbaumJNTransthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer’s disease?Mol Neurodegener201167922112803
   PubMed Web of Science ®Google Scholar
• RefaiEDekkiNYangSNTransthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion couplingProc Natl Acad Sci U S A200510247170201702516286652
   PubMed Web of Science ®Google Scholar
• ChristmanssonLBetsholtzCGustavssonÅJohanssonBSlettenKWestermarkPThe transthyretin cDNA sequence is normal in transthyretin-derived senile systemic amyloidosisFEBS Lett19912811771802015890
   PubMed Web of Science ®Google Scholar
• SteinKStorkelSLinkeRPGoebelHHChemical heterogeneity of amyloid in the carpal tunnel syndromeVirchows Arch A Pathol Anat Histopathol1987412137453120402
   PubMedGoogle Scholar
• RockenCSaegerWLinkeRPGastrointestinal amyloid deposits in old agePathol Res Pract19941906416497808962
   PubMed Web of Science ®Google Scholar
• HurshmanARWhiteJTPowersETKellyJWTransthyretin aggregation under partially denaturing conditions is a downhill polymerizationBiochemistry200443237365738115182180
   PubMed Web of Science ®Google Scholar
• ColonWKellyJWPartial denaturation of transthyretin is sufficient for amyloid fibril formation in vitroBiochemistry19923136865486601390650
   PubMed Web of Science ®Google Scholar
• SekijimaYWisemanRLMattesonJThe biological and chemical basis for tissue-selective amyloid diseaseCell20051211738515820680
   PubMed Web of Science ®Google Scholar
• SousaACoelhoTSequeirosJParental transmission and age of onset in Familial Amyloidotic Polyneuropathy (Portuguese type)Amyloid and AmyloidosisKluwer1991691693
   Google Scholar
• CoelhoTCarvalhoMSaraivaMAlvesIAlmeidaMRCostaPPA strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119J Rheumatol199320179
   Google Scholar
• JacobsonDRMcFarlinDEKaneIBuxbaumJNTransthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvementHum Genet19928933533561351039
   PubMed Web of Science ®Google Scholar
• SousaACoelhoTLobatoLSequeirosJAnticipation of Age of Onset in Familial Amyloidotic Polyneuropathy (Portuguese type)Philadelphia, PAKluwer Academic Publishers1990694697
   Google Scholar
• AndradeCA peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nervesBrain19527540842712978172
   PubMed Web of Science ®Google Scholar
• CostaPPFigueiraASBravoFRAmyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathyProc Natl Acad Sci U S A19787544994503279930
   PubMed Web of Science ®Google Scholar
• ArakiSMawatariSOhtaMNakajimaAKuroiwaYPolyneuritic amyloidosis in a Japanese familyArch Neurol19681865936025652991
   PubMedGoogle Scholar
• DruggeUAnderssonRChizariFFamilial amyloidotic polyneuropathy in Sweden: a pedigree analysisJ Med Genet1993303883928100581
   PubMed Web of Science ®Google Scholar
• YoshiokaKFuruyaHSasakiHSaraivaMJMCostaPPSakakiYHaplotype analysis of familial amyloidotic polyneuropathy. Evidence for multiple origins of the Val-Met mutation most common to the diseaseHum Genet1989829132714785
   PubMed Web of Science ®Google Scholar
• HolmgrenGCostaPMAnderssonCGeographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rateJ Med Genet1994313513548064809
   PubMed Web of Science ®Google Scholar
• HardellLHolmgrenGSteenLFredriksonMAxelsonOOccupational and other risk factors for clinically overt familial amyloid polyneuropathyEpidemiology199565986018589090
   PubMed Web of Science ®Google Scholar
• Plante-BordeneuveVSaidGFamilial amyloid polyneuropathyLancet Neurol201110121086109722094129
   PubMed Web of Science ®Google Scholar
• SuhrOBEriczonBGFrimanSLong-term follow-up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type)Liver Transpl20028978779412200779
   PubMed Web of Science ®Google Scholar
• HolmgrenGEriczonBGGrothCGClinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosisLancet1993341111311168097803
   PubMed Web of Science ®Google Scholar
• WilczekHELarssonMEriczonBGLong-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR)Amyloid201118Suppl 1188190
   Google Scholar
• SuhrODanielssonAHolmgrenGSteenLMalnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathyJ Intern Med199423554794858182405
   PubMed Web of Science ®Google Scholar
• YazakiMTokudaTNakamuraACardiac amyloid in patients with familial amyloidotic polyneuropathy consists of abundant wild-type transthyretinBiochem Biophys Res Commun200027470270610924339
   PubMed Web of Science ®Google Scholar
• BarreirosAPPostFHoppe-LotichiusMLiver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experienceLiver Transpl201016331432320209591
   PubMed Web of Science ®Google Scholar
• AndoYEriczonBGSuhrOBTashimaKAndoMReuse of a Japanese familial amyloidotic polyneuropathy patient’s liver for a cancer patient: the domino liver transplantation procedureIntern Med199736118479392364
   PubMed Web of Science ®Google Scholar
• MonteiroEPerdigotoRFurtadoALLiver transplantation for familial amyloid polyneuropathyHepatogastroenterology19984523137513809840068
   PubMedGoogle Scholar
• StangouAJHeatonNDHawkinsPNTransmission of systemic transthyretin amyloidosis by means of domino liver transplantationN Engl J Med200535222235615930432
   PubMed Web of Science ®Google Scholar
• MiroyGJLaiZLashuelHAPetersonSAStrangCKellyJWInhibiting transthyretin amyloid fibril formation via protein stabilizationProc Natl Acad Sci U S A19969315051150568986762
   PubMed Web of Science ®Google Scholar
• BauresPWOzaVBPetersonSAKellyJWSynthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acidBioorg Med Chem1999771339134710465408
   PubMed Web of Science ®Google Scholar
• Adamski-WernerSLPalaninathanSKSacchettiniJCKellyJWDiflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesisJ Med Chem200447235537414711308
   PubMed Web of Science ®Google Scholar
• BerkJLDyckPJObiciLThe diflunisal trial: update on study drug tolerance and disease progressionAmyloid201118Suppl 119119222080762
   PubMed Web of Science ®Google Scholar
• ReixachNFossTRSantelliEPascualJKellyJWBuxbaumJNHuman-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. A lesson in the generation of transgenic models of diseases involving oligomeric proteinsJ Biol Chem200828342098210718006495
   PubMed Web of Science ®Google Scholar
• JohnsonSMConnellySFearnsCPowersETKellyJWThe transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drugJ Mol Biol201218520322244854
   PubMed Web of Science ®Google Scholar
• BulawaCEConnellySDevitMTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProc Natl Acad Sci U S A2012109249629963422645360
   PubMed Web of Science ®Google Scholar
• CoelhoTMaiaLFMartins da SilvaATafamidis for transthyretin familial amyloid polyneuropathyNeurology20127918
   Web of Science ®Google Scholar
• DyckPJLitchyWJDaubeJRIndividual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility, and concordance with impairmentMuscle Nerve200327220221012548528
   PubMed Web of Science ®Google Scholar
• VinikEJHayesRPOglesbyAThe development and validation of the Norfolk QOL-DN, a new measure of patients’ perception of the effects of diabetes and diabetic neuropathyDiabet Technol Ther200573497508
   PubMedGoogle Scholar
• KimDHZeldenrustSRLowPADyckPJQuantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathyMuscle Nerve200940336337019618439
   PubMed Web of Science ®Google Scholar
• FeinsteinARClinical Epidemiology: The Architecture of Clinical ResearchPhiladelphia, PAW.B. Saunders Company1985
   Google Scholar
• KatzRJillapalliDLuanJPeripheral and central nervous System Drugs Advisory Committee Meeting, Background package 24 May 2012 Available at www.fda.gov/downloads/AdvisorycommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdviso-ryCommittee/UCM304830.pdf
   Google Scholar
• YamashitaTAndoYOkamotoSLong-term survival after liver transplantation in patients with familial amyloid polyneuropathyNeurology201278963764322345221
   PubMed Web of Science ®Google Scholar
• KristenAVLehrkeSBussSGreen tea halts progression of cardiac transthyretin amyloidosis: an observational reportClin Res Cardiol20121011080581322584381
   PubMed Web of Science ®Google Scholar
• ObiciLCorteseALozzaADoxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II studyAmyloid201219Suppl 1343622551192
   PubMed Web of Science ®Google Scholar
• SaundersAMStrittmatterWJSchmechelDAssociation of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s diseaseNeurology199343146714728350998
   PubMed Web of Science ®Google Scholar
• BottoMHawkinsPNBickerstaffMCAmyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component geneNat Med1997388558599256275
   PubMed Web of Science ®Google Scholar
• PepysMBHerbertJHutchinsonWLTargeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosisNature2002417688625425912015594
   PubMed Web of Science ®Google Scholar
• AlvarezRBorlandTChenQALN-TTR, an RNAi therapeutic for the treatment of Transthyretin-mediated amyloidosisAmyloid201017s15152
   Google Scholar
• BensonMDPandeySWitchellDAntisense oligonucleotide therapy for TTR amyloidosisAmyloid201118Suppl 15521838431
   PubMed Web of Science ®Google Scholar